摘要
胰腺癌恶性程度高,临床疗效极差。近年来,在提高胰腺癌患者治愈率和生存率方面,仍然收效甚微。因此,迫切需要提高对胰腺癌的认识以及获得更准确的疾病信息,帮助开展个体化治疗。传统高通量测序技术对胰腺癌的研究主要是鉴定与胰腺癌发生和发展相关的“驱动基因”,但却忽略了胰腺癌的肿瘤异质性。单细胞测序技术作为一种新兴技术,可以显著弥补传统测序技术的不足。在单个细胞的不同组学水平上,对恶性肿瘤的异质性、肿瘤的发生和发展、肿瘤耐药以及肿瘤治疗等多个方面进行深入探讨。本文阐述了单细胞测序技术在胰腺癌研究中的应用进展。
Pancreatic cancer has a high degree of malignancy and a very poor clinical efficacy,and little effect has been achieved on improving the cure rate and survival rate of pancreatic cancer patients in recent years.Therefore,there is an urgent need to raise awareness of pancreatic cancer in order to help obtain more accurate disease information for personalized treatment.Traditional high throughput sequencing technology is mainly used to identify the driving genes associated with the occurrence and development of pancreatic cancer,but it ignores the tumor heterogeneity in pancreatic cancer.As an emerging technology,single cell sequencing technology can significantly make up for the shortcomings of traditional sequencing technology.Conduct in-depth exploration on the heterogeneity of malignant tumors,tumor occurrence and development,tumor resistance,and tumor treatment at different omics levels of individual cells.This review mainly summarizes the application of single cell sequencing technology in the study of pancreatic cancer.
作者
姚鸿飞
杨建宇
张军峰
YAO Hongfei;YANG Jianyu;ZHANG Junfeng(Department of Biliary and Pancreatic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China)
出处
《肿瘤》
CAS
CSCD
北大核心
2022年第11期761-765,共5页
Tumor
关键词
胰腺癌
单细胞测序
肿瘤微环境
异质性
Pancreatic cancer
Single cell sequencing
Tumor microenvironment
Heterogeneity
作者简介
Correspondence to:张军峰,E-mail:zball2004@yeah.net
